Recent Progress in the Development of Small Molecule c-Met Inhibitors
C-Met, also referred to as Hepatocyte Growth Factor Receptor (HGFR), is a heterodimeric receptor tyrosine kinase. It has been determined that c-Met gene mutations, overexpression, and amplification also occur in a variety of human tumor types, and these events are closely related to the aberrant activation of the HGF/c-Met signaling pathway. Meanwhile, high c-Met expression is closely associated with poor prognosis in cancer patients. The c-Met kinase has emerged as an attractive target for developing antitumor agents. In this review, we cover the recent advances on the small molecule c-Met inhibitors discovered from 2018 until now, with a main focus on the rational design, synthesis and structureactivity relationship analysis.
No Supplementary Data
No Article Media
Document Type: Review Article
Publication date: June 1, 2019
This article was made available online on July 17, 2019 as a Fast Track article with title: "Recent Progress in the Development of Small Molecule c-Met Inhibitors".